Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01380353 · ClinicalTrials.gov registry record · Early Phase 1
Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine
A Early Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT01380353 is a Early Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 30 participants.
The verdict
NCT01380353, a Early Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to look for ways to improve breast cancer treatment by giving breast cancer drugs through the skin of the breast. The drug used in this study is a diclofenac epolamine patch and is a nonsteroid anti-inflammatory pain reliever. The drug amount that gathers in the breast, after application of a patch to the skin of the breast, will be measured and compared to the amount that is found in the breast when the patch is applied to the skin of the belly.
Interventions
- DRUG Diclofenac epolamine patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-11-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01380353
The ClinicalTrials.gov registry entry for NCT01380353 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diclofenac epolamine patch is the first listed.
NCT01380353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01380353 about?
NCT01380353 is a clinical study titled "Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine". The purpose of this study is to look for ways to improve breast cancer treatment by giving breast cancer drugs through the skin of the breast. The drug used in this study is a diclofenac epolamine patch and is a nonsteroid anti-inflammatory pain reliever. The drug amount that gathers in the breast,...
What is the current status of trial NCT01380353?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2011-06. Estimated completion is 2012-11-12.
What interventions are being tested in trial NCT01380353?
The interventions under investigation include: Diclofenac epolamine patch (DRUG).
Who is sponsoring clinical trial NCT01380353?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.